Although there are several effective anti-osteoporosis drugs on the market today, new therapies with improved safety profiles and efficacy are still needed. The FDA called osteoporosis-related ...

The 2026 Medicare Physician Fee Schedule (MPFS) is certainly creating a lot of noise. The critical issue with the MPFS that no one talks about — also known as Medicare Part B — is there is not a ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

After months of hospital stays, a Macon family is finally home for the holidays after their son’s medical emergency required ...